Advertisement

Kutane Lymphome

  • Lucie Heinzerling
  • Anke Hartmann
  • Martina Hund
Chapter
  • 296 Downloads

Zusammenfassung

Kutane Lymphome (cutaneous lymphomas: CL) umfassen die Gruppe der kutanen T-Zell-Lymphome (cutaneous T-cell lymphomas: CTCL), kutanen B-Zell-Lymphome (cutaneous B-cell lymphomas: CBCL) und die sog. hämatodermischen Neoplasien (HN). CL gehören zur Gruppe der Non-Hodgkin-Lymphome (NHL) und stellen in der Subgruppe der extranodalen NHL die zweithäufigste Gruppe hinter den gastrointestinalen Lymphomen dar (Jaffe et al. 2009). Man unterscheidet zwischen primären und sekundären CL. Primäre CL haben ihren Ursprung in der Haut und bleiben in der Regel darauf auch längere Zeit beschränkt, während sekundäre CL kutane Manifestationen von primär nodalen oder extranodalen Lymphomen darstellen (Willemze 2005). Die primären CL unterscheiden sich hinsichtlich klinischem Verlauf, Therapieoptionen und Prognose erheblich von nodalen und extrakutanen Lymphomen. So zeigen z. B. die primär kutanen CD30+-T-Zell-Lymphome einen gutartigen Verlauf, wogegen die nodalen Varianten als aggressiv eingestuft werden. Da die CL zumeist weniger aggressiv sind, werden sie auch weniger aggressiv behandelt.

Literatur

  1. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ (2009) Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 160:1299–1307PubMedCrossRefGoogle Scholar
  2. Alsaleh QA, Nanda A, Baker H, Al-Sabah H, Calonje E (2004) Unilesional (segmental) mycosis fungoides presenting in childhood. Pediatr Dermatol 21: 558–560PubMedCrossRefGoogle Scholar
  3. Assaf C, Gellrich S, Steinhoff M, Nashan D, Weisse F, Dippel E, Coors E, Stein A, Gollin P, Henke U, Adam-Murati S, Koch A, Klemke CD, Stadler R, Sterry W (2007a) Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 5:662–668PubMedCrossRefGoogle Scholar
  4. Assaf C, Gellrich S, Whittaker S et al (2007b) CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer. J Clin Pathol 60:981–989PubMedPubMedCentralCrossRefGoogle Scholar
  5. Bekkenk MW, Geelen FA,. van Voorst Vader PC, Heule F, Geerts ML, van Vloten W A, Meijer CJ, Willemze R (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the longterm follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661Google Scholar
  6. Bekkenk MW, Vermeer MH, Jansen PM et al. (2003) Peripheral T-cell-lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 102:2213–2219PubMedCrossRefGoogle Scholar
  7. Bekkenk MW, Jansen PM, Meijer CJ et al. (2004) CD56+ haematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 15:1097–110PubMedCrossRefGoogle Scholar
  8. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson RL (2001) Induction of human tumor-loaded dendritic cells. Int J Cancer 91:438–447PubMedCrossRefPubMedCentralGoogle Scholar
  9. Bernengo MG1, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, Fierro MT (2007) Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 92: 784-794Berti E, Tomasini D, Vermeer MH et al. (1999) Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell-lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 155: 483–492PubMedCrossRefGoogle Scholar
  10. Bunn PA, Lamberg SI (1979) Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 63:725–728Google Scholar
  11. Burg G, Kempf W, Cozzio A, Feit J, Willemze R, S Jaffe E, Dummer R, Berti E, Cerroni L, Chimenti S, Diaz-Perez JL, Grange F, Harris NL, Kazakov DV, Kerl H, Kurrer M, Knobler R, Meijer CJ, Pimpinelli N, Ralfkiaer E, Russell-Jones R, Sander C, Santucci M, Sterry W, Swerdlow SH, Vermeer MH, Wechsler J, Whittaker S (2005) WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 32:647–674PubMedCrossRefGoogle Scholar
  12. Cerroni L, Zochling N, Putz B, Kerl H (1997) Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 24:457–461PubMedCrossRefGoogle Scholar
  13. Clark C, Dawe RS, Evans AT, Lowe G, Ferguson J (2000) Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol 136: 748–752Google Scholar
  14. Coors EA, von den Driesch P (2000) Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 143: 127–131PubMedCrossRefGoogle Scholar
  15. d’Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H (2010) Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 150:565–573PubMedCrossRefGoogle Scholar
  16. de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela JM, Bachelez H, Bensussan A, Michel L, Bagot M (2014) Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 170: 720–724PubMedCrossRefGoogle Scholar
  17. Dummer R, Häffner AC, Hess M, Burg G (1996a) A rational approach to the therapy of cutaneous T-cell lymphomas. Onkologie 19:226–230CrossRefGoogle Scholar
  18. Dummer R, Potoczna N, Häffner A, Gilardi F, Zimmermann D, Burg G (1996b) A primary cutaneous non-T non-B CD4+, CD56+ lymphoma. Arch Derm 132: 550–553PubMedCrossRefPubMedCentralGoogle Scholar
  19. Dummer R, Assaf C, Bagot M, Gniadecki R, Hauschild A, Knobler R, Ranki A, Stadler R, Whittaker S (2007) Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 43:2321–2329PubMedCrossRefGoogle Scholar
  20. Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C (2012). Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.Leuk Lymphoma; 53: 1501–1508Google Scholar
  21. Dummer R1, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R (2012) Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30: 4091–4097PubMedCrossRefPubMedCentralGoogle Scholar
  22. Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Ann Oncol 25:1807–1812PubMedCrossRefPubMedCentralGoogle Scholar
  23. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC (2001) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137:581–593Google Scholar
  24. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19: 2456–2471PubMedCrossRefPubMedCentralGoogle Scholar
  25. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH (2015) Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood 125: 1883–1889PubMedPubMedCentralCrossRefGoogle Scholar
  26. Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4: 180–188PubMedCrossRefGoogle Scholar
  27. Felcht M, Booken N, Stroebel P, Goerdt S, Klemke CD (2011) The value of molecular diagnostics in primary cutaneous B-cell lymphomas in the context of clinical findings, histology, and immunohistochemistry. J Am Acad Dermatol 64:135–143CrossRefGoogle Scholar
  28. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo mg (1998) Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 31:583–588CrossRefGoogle Scholar
  29. Foss F (2003) Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymph 44 (Suppl 3):55–61CrossRefGoogle Scholar
  30. Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene ans denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106: 454–457PubMedCrossRefGoogle Scholar
  31. Foss F, Duvic M, Lerner A, Waksman J, Whittaker S (2016) Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk 16:637–643CrossRefGoogle Scholar
  32. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, Audring H, Sterry W (2005) Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation. Br J Dermatol 153:167–173PubMedCrossRefGoogle Scholar
  33. Go RS, Wester SM (2004) Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-lie T-cell-lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer 101: 1404–1413PubMedCrossRefGoogle Scholar
  34. Goodlad JR, Davidson MM, Hollowood K, Batstone P, Ho-Yen DO (2000) Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 37:501–508PubMedCrossRefPubMedCentralGoogle Scholar
  35. Grange F, Bekkenk MW, Wechsler J, Meijer CJ, Cerroni L, Bernengo M, Bosq J, Hedelin G, Fink Puches R, van Vloten WA, Joly P, Bagot M, Willemze R (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602–3610PubMedCrossRefPubMedCentralGoogle Scholar
  36. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121–3127PubMedCrossRefGoogle Scholar
  37. Heald P, Rook A, Perez M, Wintroub B, Knobler R, Jegasothy B, Gasparro F, Berger C, Edelson R (1992) Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 27:427–433PubMedCrossRefGoogle Scholar
  38. Heinzerling L, Dummer R, Kempf W, Hess-Schmid M, Burg G (2000) Intralesional therapy with anti-CD20-antibody in primary cutaneous B-cell Lymphoma. Arch Derm 136: 374–378Google Scholar
  39. Heinzerling M, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, vondenDriesch P, Dummer R (2000) Reduction of tumor burden and stablization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphomas. Cancer 89:1835–1844PubMedCrossRefPubMedCentralGoogle Scholar
  40. Hönigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K (1984) Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J Am Acad Dermatol 10:238–245PubMedCrossRefGoogle Scholar
  41. Humme D, Nast A, Erdmann R, Vandersee S, Beyer M (2014). Systematic review of combination therapies for mycosis fungoides.Cancer Treat Rev 40: 927–933PubMedCrossRefPubMedCentralGoogle Scholar
  42. Illidge T, Chan C, Counsell N, Morris S, Scarisbrick J, Gilson D, Popova B, Patrick P, Smith P, Whittaker S, Cowan R (2013). Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. Br J Cancer 109: 2566–2573PubMedPubMedCentralCrossRefGoogle Scholar
  43. Jaffe SE (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program: 523–531CrossRefGoogle Scholar
  44. Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, Paul C, Chaoui D, Sigal-Grinberg M, Morel P, Dubertret L, Bachelez H (2009) Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol 161:660–663PubMedCrossRefPubMedCentralGoogle Scholar
  45. Jones GW, Rosenthal D, Wilson LD (1999) Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer 85:1985–1995Google Scholar
  46. Kavanaugh SM, White LA, Kolesar JM (2010) Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. Am J Health Syst Pharm 67: 793–797PubMedCrossRefPubMedCentralGoogle Scholar
  47. Kerl K, Prins C, Saurat JH, French LE (2006) Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol 155:1197–1200PubMedCrossRefPubMedCentralGoogle Scholar
  48. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr (1987) Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 123:201–204PubMedCrossRefGoogle Scholar
  49. Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, Whittaker S, Illidge TM, Schwarz T, Kaufmann R, Cooper K, Knudsen KM, Lisby S, Baadsgaard O, Knox SJv (2007) Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 109:4655–4662PubMedCrossRefPubMedCentralGoogle Scholar
  50. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, et al.; MAVORIC Investigators (2018) Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19:1192–1204.Google Scholar
  51. Knobler R, Girardi M (2001) Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann N Y Acad Sci 941:123–138CrossRefGoogle Scholar
  52. Knospe WH (1974) Malignant lymphoma. 2. Therapy. Postgrad Med 55:211–218PubMedCrossRefGoogle Scholar
  53. Korgavkar K, Xiong M, Weinstock M (2013). Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 149: 1295–1299PubMedCrossRefGoogle Scholar
  54. Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L (1997) Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol 36:311–314PubMedCrossRefGoogle Scholar
  55. Kuzel TM, Roenigk HH Jr, Samuelson E, Herrmann JJ, Hurria A, Rademaker AW, Rosen ST (1995) Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J Clin Oncol 13:257–263PubMedCrossRefGoogle Scholar
  56. Lansigan F, Foss FM (2010) Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 70:273–786PubMedCrossRefGoogle Scholar
  57. Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A (2003) Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101: 4267–4272PubMedCrossRefGoogle Scholar
  58. Mann BS, Johnson JR, He K, Sridhara R, Abraham S, Booth BP, Verbois L, Morse DE, Jee JM, Pope S, Harapanhalli RS, Dagher R, Farrell A, Justice R, Pazdur R (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res 13:2318–2322PubMedCrossRefGoogle Scholar
  59. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo mg, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 104: 2437–2441PubMedCrossRefGoogle Scholar
  60. Maza S, Gellrich S, Assaf C, Beyer M, Spilker L, Orawa H, Munz DL, Sterry W, Steinhoff M (2008) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. Leuk Lymphoma 49:1702–1709CrossRefGoogle Scholar
  61. McGirt LY, Thoburn C, Hess A, Vonderheid EC (2010) Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed 26:182–191CrossRefGoogle Scholar
  62. Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, Servitje O (2010) Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases. J Am Acad Dermatol 62(3):418–26PubMedCrossRefPubMedCentralGoogle Scholar
  63. Natkunam Y, Smoller BR, Zehnder JL, Dorfman RF, Warnke RA (1999) Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol 23:571–581PubMedCrossRefPubMedCentralGoogle Scholar
  64. Niakosari F, Sur M (2007) Agranular CD4+/ CD56+ Hematodermic Neoplasm. A distinct entity described in the recent World Health Organization-European Organization for Research and Treatment of Cancer Classification for Cutaneous Lymphomas Arch Pathol Lab Med 131:149–151Google Scholar
  65. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376–388PubMedCrossRefPubMedCentralGoogle Scholar
  66. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo mg, Sterry W, Laroche L, Trautinger F, Whittaker S; ISCL/EORTC (2007) Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713–1722PubMedCrossRefPubMedCentralGoogle Scholar
  67. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M (2011) Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64:352–404PubMedCrossRefPubMedCentralGoogle Scholar
  68. Paul T, Radny P, Krober SM, Paul A, Blaheta HJ, Garbe C (2001) Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol 144:1239–1243PubMedCrossRefPubMedCentralGoogle Scholar
  69. Petrella T, Dalac S, Maynadié M, Mugneret F, Thomine E, Courville P, Joly P, Lenormand B, Arnould L, Wechsler J, Bagot M, Rieux C, Bosq J, Avril MF, Bernheim A, Molina T, Devidas A, Delfau-Larue MH, Gaulard P, Lambert D (1999) CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d’Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 23:137–146PubMedCrossRefPubMedCentralGoogle Scholar
  70. Petrella T, Comeau MR, Maynadie M et al. (2002) Agranular CD4+ CD56+ hematodermic neoplasm (blastic NK-cell-lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 26:852–862PubMedCrossRefGoogle Scholar
  71. Piccinno R, Caccialanza M, Berti E (2003) Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol 13:49–52Google Scholar
  72. Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S (2007) Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 25:3168–3173PubMedCrossRefGoogle Scholar
  73. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group (2017) Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 17: 31266–31267Google Scholar
  74. Quereux G, Marques S, Nguyen JM, Bedane C, D’incan M, Dereure O, Puzenat E, Claudy A, Martin L, Joly P, Delaunay M, Beylot-Barry M, Vabres P, Celerier P, Sasolas B, Grange F, Khammari A, Dreno B (2008) Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144(6):727–733Google Scholar
  75. Querfeld C, Mehta N, Rosen ST, Guitart J, Rademaker A, Gerami P, Kuzel TM (2009) Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 50:1969–1976CrossRefGoogle Scholar
  76. Ramsay DL, Lish KM, Yalowitz CB, Soter NA (1992) Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128:931–933PubMedCrossRefGoogle Scholar
  77. Rezania D, Sokol L, Cualig HD (2007) Classification and treatment of rare and aggressive types of peripheral T-cell( natural killer-cell lymphomas of the skin. Cancer Control 14:112–123PubMedCrossRefGoogle Scholar
  78. Roenigk HH Jr, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA Jr, et al. (1990) Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95: 198S–205SCrossRefGoogle Scholar
  79. Roggero E, Zucca E, Mainetti C, Bertoni F, Valsangiacomo C, Pedrinis E, Borisch B, Piffaretti JC, Cavalli F, Isaacson PG (2000) Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 31:263–268PubMedCrossRefGoogle Scholar
  80. Rook AH, Suchin KR, Kao DM, Yoo EK, Macey WH, DeNardo BJ, Bromely PG, Geng Y, Junkins-Hopkins JM, Lessin SR (1999) Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 4:85–90CrossRefGoogle Scholar
  81. Ruddle JB, Harper CA, Hönemann D, Seymour JF, Prince HM (2006) A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol 90:1070–1071PubMedCrossRefGoogle Scholar
  82. Russell Jones, R (2000) Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 142:16–21PubMedCrossRefGoogle Scholar
  83. Savoia P, Fierro MT, Novelli M, Quaglino P, Verrone A, Geuna M, Bernengo mg (1997) CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 137:966–971PubMedCrossRefGoogle Scholar
  84. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, Wain EM (2012) U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168(1):192–200PubMedCrossRefGoogle Scholar
  85. Schmoll H-J, Höffgen K, Possinger K (2006) Kompendium Internistische Onkologie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  86. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R (2008) European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 112:1600–1609PubMedCrossRefGoogle Scholar
  87. Shimada K, Kinoshita T, Naoe T, Nakamura S (2009) Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10:895–902PubMedCrossRefGoogle Scholar
  88. Slater DN (2005) The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol 153:874–880PubMedCrossRefGoogle Scholar
  89. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, Sterry W (1998) Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92:3578–3581Google Scholar
  90. Stadler R, Assaf C, Klempke CD, Nashan D, Weichenthal M, Dummer R, Sterry W (2008) Kurzleitlinie – Kutane Lymphome. JDDGSuppl. 1: S29–S35Google Scholar
  91. Stadler R, Assaf C, Klempke CD, Nashan D, Weichenthal M, Dummer R, Sterry W (2012) SK2 – Kurzleitlinie – Kutane Lymphone (ICS10 C82-C86) Update 2012. ADO-homepage.deGoogle Scholar
  92. Stevens SR, Bowen GM, Duvic M, King LE, Knobler R, Lim HW, Margolis D, Parry EJ, Rook AH, Stricklin GP, Suchin KR, Tharp MD, Vonderheid E, Zic JA (1999) Effectiveness of photopheresis in Sezary syndrome. Arch Dermatol 135:995–997CrossRefGoogle Scholar
  93. Straus DJ1, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S (2007). Results of a phase II trial of oral bexarotene (Targretin) combined ‘with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 109: 1799–1803PubMedCrossRefGoogle Scholar
  94. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375–2390PubMedPubMedCentralCrossRefGoogle Scholar
  95. Thomas A, Teicher BA, Hassan R (2016) Antibody-drug conjugates for cancer therapy. Lancet Oncol 17: 254-262 Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, D’Incan M, Ranki A, Pimpinelli N, Ortiz-Romero P, Dummer R, Estrach T, Whittaker S (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42:1014–1030Google Scholar
  96. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke CD, Ortiz-Romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R (2017) European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer 77: 57–74PubMedCrossRefGoogle Scholar
  97. Vonderheid EC, Bernengo mg, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pittelkow M, Russell-Jones R, Takigawa M, Willemze R; ISCL (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95–106Google Scholar
  98. van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, Jack A, Van’t Veer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A (2006) Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 108:3295–3301PubMedCrossRefPubMedCentralGoogle Scholar
  99. von den Driesch P, Coors EA (2002) Localized cutaneous small to medium-sized pleomorphic T-cell-lymphoma: a report of 3 cases stable for years. J Am Acad Dermatol 46:531–535Google Scholar
  100. Weinstock, M A (1994) Epidemiology of mycosis fungoides. Semin Dermatol 13:154–159Google Scholar
  101. Whittaker S, Ortiz P, Dummer R, Ranki A, Hasan B, Meulemans B, Gellrich S, Knobler R, Stadler R, Karrasch M (2012) Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol 167: 678–687Google Scholar
  102. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768–3785PubMedCrossRefPubMedCentralGoogle Scholar
  103. Willemze R, Jansen PM, Cerroni L et al. (2008) Subcutaneous panniculitis-like T-cell-lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 111:838–845PubMedCrossRefPubMedCentralGoogle Scholar
  104. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-López AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342PubMedCrossRefPubMedCentralGoogle Scholar
  105. Wollina U, Graefe T, Kaatz M (2001) Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up. Ann N Y Acad Sci 941:214–216CrossRefGoogle Scholar
  106. Wollina U, Dummer R, Brockmeyer NH et al. (2003) Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98:99–1001Google Scholar
  107. Wood GS, Tung RM, Haeffner AC, Crooks CF, Liao S, Orozco R, Veelken H, Kadin M E, Koh H, Heald P, Barnhill RL, Sklar J (1994) Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 103:34–41PubMedCrossRefPubMedCentralGoogle Scholar
  108. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R SO (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29(33): 4410–4416PubMedCrossRefGoogle Scholar
  109. Zackheim HS, Epstein EH Jr. (1989) Low-dose methotrexate for the Sezary syndrome. J Am Acad Dermatol 21:757–762PubMedCrossRefGoogle Scholar
  110. Zackheim HS, Kashani-Sabet M, Hwang ST (1996) Lowdose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 34:626–631PubMedCrossRefGoogle Scholar
  111. Zackheim HS, Kashani Sabet M, Amin S (1998) Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 134:949–954Google Scholar
  112. Zenahlik P, Fink Puches R, Kapp KS, Kerl H, Cerroni L (2000) Die Therapie der primaren kutanen B-Zell-Lymphome. Hautarzt 51:19–24CrossRefGoogle Scholar
  113. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Sabattini E, Pileri S, Baccarani M (2007) Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25:4293–4297PubMedCrossRefGoogle Scholar
  114. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21:860–863PubMedCrossRefGoogle Scholar
  115. Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, d’Amore F, Haioun C, Thieblemont C, González-Barca E, García CG, Johnson PW, van Imhoff GW, Ng T, Dwyer K, Morschhauser F (2016) European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.Haematologica 101:e407–e410PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Lucie Heinzerling
    • 1
  • Anke Hartmann
    • 1
  • Martina Hund
    • 2
  1. 1.Universitätsklinikum ErlangenErlangenDeutschland
  2. 2.Rzany und HundBerlinDeutschland

Personalised recommendations